Filtered By:
Condition: Heart Failure
Procedure: Heart Valve Surgery

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 447 results found since Jan 2013.

Clinical outcome in nonagenarians undergoing transcatheter valve replacement.
CONCLUSION: Our case series demonstrate that even with elevated comorbidity index, clinical endpoints and valve-associated results are relatively favorable in nonagenarians treated with TAVR. PMID: 29054182 [PubMed - in process]
Source: Indian Heart J - September 1, 2017 Category: Cardiology Authors: Mendiz O, Fava C, Cura F, Agatiello C, Sztejfman M, Damonte A, Londero H, Candiello A, Berrocal D Tags: Indian Heart J Source Type: research

Long ‐term outcomes for different surgical strategies to treat left ventricular outflow tract obstruction in hypertrophic cardiomyopathy
ConclusionSeptal myectomy is a safe procedure resulting in symptomatic improvement in the majority of patients. The annual incidence of non‐fatal disease‐related complications after surgical treatment of LVOTO is relatively high. Patients who underwent MV replacements had poorer outcomes with less symptomatic benefit in spite of a similar reduction in LVOT gradients.
Source: European Journal of Heart Failure - November 16, 2017 Category: Cardiology Authors: Richard Collis, Oliver Watkinson, Constantinos O'Mahony, Oliver P. Guttmann, Antonis Pantazis, Maria Tome ‐Esteban, Victor Tsang, Venkatachalam Chandrasekaran, Christopher G.A. McGregor, Perry M. Elliott Tags: Research Article Source Type: research

Efficacy and Efficiency of Perioperative Stellate Ganglion Blocks in Cardiac Surgery: A Pilot Study
Nationally, postoperative atrial fibrillation (POAF) occurs in up to 40% of patients after coronary artery bypass grafting (CABG), 50% of patients after valve surgery, 64% of patients after mitral valve and CABG, and 49% after aortic valve replacement.1 Atrial fibrillation worsens a patient ’s hemodynamic status and increases the risk of congestive heart failure, embolic events, and longer intensive care unit stays, leading to increased patient morbidity and strain on financial resources. In the United States, POAF carries a higher risk of stroke, worsened survival, and an additional 4.9 days and $10,000 to $11,500 in hospital stay costs.
Source: Journal of Cardiothoracic and Vascular Anesthesia - November 20, 2017 Category: Anesthesiology Authors: Christopher W. Connors, Wendy Y. Craig, Scott A. Buchanan, Justin M. Poltak, James B. Gagnon, Craig S. Curry Tags: Letter to the Editor Source Type: research

Mitral valve pressure gradient after percutaneous mitral valve repair: every beat counts
Abstract A patient presented with symptoms of decompensated heart failure 2 months after percutaneous mitral valve (MV) repair. Echocardiography demonstrated impaired left ventricular function with elevated MV pressure gradients and pulmonary pressures during rapid atrial fibrillation. Heart rate control was achieved by implantation of a biventricular pacemaker with subsequent His‐bundle ablation because atrial fibrillation was refractory to medical treatment. During biventricular pacing at different rates (50–110 b.p.m.), heart rate correlated positively with both MV mean pressure gradient and global longitudinal st...
Source: ESC Heart Failure - November 23, 2017 Category: Cardiology Authors: Daniel Lavall, Bruno Scheller, Christian Werner, Axel Buob, Felix Mahfoud Tags: Case Report Source Type: research

Initial experience with percutaneous edge-to-edge transcatheter mitral valve repair in a tertiary medical center in Taiwan
Conclusion Trans-catheter edge-to-edge mitral valve repairs are safe and effective in Asians with symptomatic SMR, regarding the improvements of clinical symptoms and exercise capacities. MitraClips is also associated with reverse remodeling of pulmonary hypertension and left ventricular size in patients with SMR.
Source: Journal of the Chinese Medical Association - December 29, 2017 Category: General Medicine Source Type: research

Recent developments and controversies in transcatheter aortic valve implantation
Interventional cardiology has been revolutionised by transcatheter aortic valve implantation (TAVI), which has become established as the benchmark treatment for severe aortic stenosis in patients at high risk for surgical aortic valve replacement (AVR). Increased procedural familiarity and progression in device technology has enabled improvements to be made in complication rates, which have led to a commensurate expansion in the use of TAVI; it is now a viable alternative to AVR in patients at intermediate surgical risk, and has been used in cohorts such as those with bicuspid aortic valves or pure, severe aortic regurgita...
Source: European Journal of Heart Failure - January 25, 2018 Category: Cardiology Authors: Noman Ali, Peysh A. Patel, Steven J. Lindsay Tags: Review Source Type: research

Mitralign raises $10m
Mitralign, which is looking to commercialize its namesake mitral valve treatment and pursue regulatory nods for its Trialign tricuspid valve device, said it raised nearly $10 million. The $9.8 million funding, of a hoped-for $30.2 million, came from 19 unnamed investors beginning last September, the Tewksbury, Mass.-based company said in a regulatory filing. Mitralign raised a $40 million Series E round in May 2016. The Mitralign and Trialign devices are designed to use wire and catheters to implant polyester anchors within the annulus of the mitral and tricuspid valves. The anchors are then cinched together to reduce v...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Replacement Heart Valves Wall Street Beat Mitralign Inc. Source Type: news

Prevalence and Outcomes of Mitral Stenosis in Patients Undergoing Transcatheter Aortic Valve Replacement: Findings From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry
Conclusions Approximately one-tenth of patients undergoing TAVR have concomitant MS. Severe MS is an independent predictor of 1-year adverse clinical outcomes following TAVR. The higher risk for long-term adverse events must be considered when evaluating patients with combined aortic stenosis and MS for TAVR.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - April 2, 2018 Category: Cardiology Authors: Joseph, L., Bashir, M., Xiang, Q., Yerokun, B. A., Matsouaka, R. A., Vemulapalli, S., Kapadia, S., Cigarroa, J. E., Zahr, F. Tags: Structural Source Type: research

Mata-Analysis Comparing Transcatheter Versus Surgical Treatment of Paravalvular Leaks
Percutaneous paravalvular leak (PVL) closure has emerged as a feasible alternative to redo valve surgery. However, comparative data on percutaneous and surgical treatment of PVL are scarce. We performed a systematic review and a meta-analysis of studies on percutaneous and surgical treatment of PVL. Of the 2267 studies screened, 22 eligible studies were analyzed. Primary endpoints were: technical success, 30-day mortality, stroke and length-of-stay. Secondary endpoints were: 1-year mortality, readmission for heart failure, reoperation, and symptomatic improvement at follow-up.
Source: The American Journal of Cardiology - April 19, 2018 Category: Cardiology Authors: Tatiana Busu, Fahad Alqahtani, Vinay Badhwar, Chris C. Cook, Charanjit S. Rihal, Mohamad Alkhouli Source Type: research

Meta-analysis Comparing Transcatheter and Surgical Treatments of Paravalvular Leaks
Percutaneous paravalvular leak (PVL) closure has emerged as a feasible alternative to redo valve surgery. However, comparative data on percutaneous and surgical treatment of PVL are scarce. We performed a systematic review and a meta-analysis of studies on percutaneous and surgical treatments of PVL. Of the 2,267 studies screened, 22 eligible studies were analyzed. Primary end points were technical success, 30-day mortality, stroke, and length of stay. Secondary end points were 1-year mortality, readmission for heart failure, reoperation, and symptomatic improvement at follow-up.
Source: The American Journal of Cardiology - April 19, 2018 Category: Cardiology Authors: Tatiana Busu, Fahad Alqahtani, Vinay Badhwar, Chris C. Cook, Charanjit S. Rihal, Mohamad Alkhouli Source Type: research

Prognosis of Cancer Patients with Aortic Stenosis Under Optimal Cancer Therapies and Conservative Cardiac Treatments.
Authors: Okura Y, Ishigaki S, Sakakibara S, Yumoto C, Hashitate M, Sekine C, Fujita T, Takayama T, Ozaki K, Sato N, Minamino T Abstract Aortic stenosis (AS) is a life-threatening comorbidity of cancer patients. Aortic valve replacement (AVR) should be considered for some cancer patients, but neither the characteristics nor prognosis under conservative therapy is well known.We searched our echocardiography log (years 2005-2014) for cancer patients with AS, and 92 patients (54% female) were included in the study. To compare the survival curves, 470 control patients without AS were selected from our cancer registry.Me...
Source: International Heart Journal - June 9, 2018 Category: Cardiology Tags: Int Heart J Source Type: research

Long-standing persistent effects of atrial volume reduction combined with pulmonary vein isolation
Publication date: Available online 18 June 2018 Source:Journal of Cardiology Cases Author(s): Masami Takagaki, Naoko Ikeda, Hiroki Yamaguchi, Shinichi Mitsuyama, Tasuku Kadowaki, Tatsuya Nakao Although surgical left atrial (LA) volume reduction combined with mitral valve surgery and/or surgical ablation for atrial fibrillation has been reported to be effective, its long-term outcomes in the absence of mitral procedure are not well established. A 74-year-old man with two previous sternotomies—the first for pericardiectomy due to constrictive pericarditis and the second for mitral valve replacement with mechanical valve a...
Source: Journal of Cardiology Cases - June 20, 2018 Category: Cardiology Source Type: research